Interestingly, our findings reveal an apparent paradox where M1-shifted macrophages (higher CD68/CD163 ratio) are associated with adverse outcomes in JAK2-positive MPNs, contrasting with the conventional paradigm observed in solid tumors and other hematological malignancies where M2 macrophages typically drive pathology. Here, CD68 is linked to hematologic disorder.